Skip to main content

Advertisement

SpringerLink
Log in

Long-Term Failure Rates Among Interventions for Benign Prostatic Obstruction

  • REVIEW
  • Published:
Current Bladder Dysfunction Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

As novel approaches for treating bladder outlet obstruction due to benign prostatic hyperplasia proliferate, it is critical for urologists to have accurate information regarding the durability of these procedures as they counsel patients. We summarize the available data examining the rate and time course of treatment failure for common contemporary procedures.

Recent Findings

There is significant clinical variability between procedures for benign prostatic hyperplasia with lack of long-term evidence for several newer procedures.

Summary

While numerous surgical approaches for benign prostatic hyperplasia are endorsed by the most recent AUA guidelines, the most durable treatments remain the most invasive. Clinicians should consider the tradeoffs between expected patient lifespan, surgical candidacy, and durability of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data Availability

All data was extracted directly from source articles and no novel data was generated. Calculations regarding mean follow up time and adjusted failure rate available on request.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Taktak S, Jones P, Haq A, Rai BP, Somani BK. Aquablation: a novel and minimally invasive surgery for benign prostate enlargement. Ther Adv Urol. 2018;10:183–8.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Garcia C, Chin P, Rashid P, Woo HH. Prostatic urethral lift: A minimally invasive treatment for benign prostatic hyperplasia. Prostate Int. 2015;3:1–5.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Westwood J, Geraghty R, Jones P, Rai BP, Somani BK. Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia. Ther Adv Urol. 2018;10:327–33.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I—initial work-up and medical management. J Urol. 2021;206:806–17.

    Article  PubMed  Google Scholar 

  5. Kordan Y, Canda AE, Köseoğlu E, Balbay D, Laguna MP, de la Rosette J. Robotic-assisted simple prostatectomy: a systematic review. J Clin Med. 2020;9:1798.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Gilfrich C, May M, Fahlenbrach C, Günster C, Jeschke E, Popken G, Stolzenburg J-U, Weissbach L, von Zastrow C, Leicht H (2021) Surgical reintervention rates after invasive treatment for lower urinary tract symptoms due to benign prostatic syndrome: a comparative study of more than 43,000 patients with long-term followup. J Urol 205:855–863. Survival analysis of reintervention directly comparing TURP, PVP, LEP, and OSP.

  7. Chen S, Zhu L, Cai J, et al. Plasmakinetic enucleation of the prostate compared with open prostatectomy for prostates larger than 100 grams: a randomized noninferiority controlled trial with long-term results at 6 years. Eur Urol. 2014;66:284–91.

    Article  CAS  PubMed  Google Scholar 

  8. Eredics K, Wachabauer D, Röthlin F, Madersbacher S, Schauer I. Reoperation rates and mortality after transurethral and open prostatectomy in a long-term nationwide analysis: have we improved over a decade? Urology. 2018;118:152–7.

    Article  PubMed  Google Scholar 

  9. Lee Z, Lee M, Keehn AY, Asghar AM, Strauss DM, Eun DD. Intermediate-term urinary function and complication outcomes after robot-assisted simple prostatectomy. Urology. 2020;141:89–94.

    Article  PubMed  Google Scholar 

  10. Shah AA, Gahan JC, Sorokin I. Comparison of robot-assisted versus open simple prostatectomy for benign prostatic hyperplasia. Curr Urol Rep. 2018;19:71.

    Article  PubMed  Google Scholar 

  11. LaBossiere JR, Wallis CJD, Herschorn S, Carr L, Saskin R, Nam R. Surgical management of benign prostatic obstruction: 20-year population-level trends. Can Urol Assoc J. 2020;14:252–7.

    PubMed  PubMed Central  Google Scholar 

  12. Malaeb BS, Yu X, McBean AM, Elliott SP. National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000-2008). Urology. 2012;79:1111–6.

    Article  PubMed  Google Scholar 

  13. Jeon BJ, Chung H, Bae JH, Jung H, Lee JG, Choi H. Analysis of present status for surgery of benign prostatic hyperplasia in Korea using nationwide healthcare system data. Int Neurourol J. 2019;23(1):22–9. https://doi.org/10.5213/inj.1836198.099.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Mordasini L, Di Bona C, Klein J, Mattei A, Wirth GJ, Iselin CE. 80-W greenlight laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic obstruction: 5-year outcomes of a single-center prospective randomized trial. Urology. 2018;116:144–9.

    Article  PubMed  Google Scholar 

  15. Chou W, Frendl D, Chen Y-W, Chang D, Kim M. Long-term rates of treatment failure for ambulatory Turp and PVP: an assessment using state-level claims data. J Urol. 2021;206:e355–5. Survival analysis comparing 10-year reoperation rates between PVP and TURP.

    Article  Google Scholar 

  16. Yasushi Y, Jun F, SugimuraYoshiki KI. Photoselective vaporization of the prostate: long-term outcomes and safety during 10 years of follow-up. J Endourol. 2016. https://doi.org/10.1089/end.2016.0522.

  17. Park J, Cho SY, Cho MC, Jeong H, Son H. 5-year long-term efficacy of 120-W GreenLight photoselective vaporization of the prostate for benign prostate hyperplasia. PLoS ONE. 2017;12:e0184442.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Calves J, Thoulouzan M, Perrouin-Verbe M-A, Joulin V, Valeri A, Fournier G. Long-term patient-reported clinical outcomes and reoperation rate after photovaporization with the XPS-180W GreenLight laser. Eur Urol Focus. 2019;5:676–80.

    Article  PubMed  Google Scholar 

  19. Das AK, Han TM, Hardacker TJ. Holmium laser enucleation of the prostate (HoLEP): size-independent gold standard for surgical management of benign prostatic hyperplasia. Can J Urol. 2020;27:44–50.

    PubMed  Google Scholar 

  20. Elkoushy MA, Elshal AM, Elhilali MM. Reoperation after holmium laser enucleation of the prostate for management of benign prostatic hyperplasia: assessment of risk factors with time to event analysis. J Endourol. 2015;29:797–804.

    Article  PubMed  Google Scholar 

  21. Enikeev D, Taratkin M, Morozov A, et al. Long-term outcomes of holmium laser enucleation of the prostate: a 5-year single-center experience. J Endourol. 2020;34:1055–63.

    Article  PubMed  Google Scholar 

  22. Kim A, Hak A-J, Choi WS, Paick SH, Kim HG, Park H. Comparison of long-term effect and complications between holmium laser enucleation and transurethral resection of prostate: nations-wide health insurance study. Urology. 2021;154:300–7. Large study demonstrating lower 7-year reoperation rate after HoLEP compared to TURP.

    Article  PubMed  Google Scholar 

  23. Krambeck AE, Handa SE, Lingeman JE. Experience with more than 1,000 holmium laser prostate enucleations for benign prostatic hyperplasia. J Urol. 2013. https://doi.org/10.1016/j.juro.2012.11.027.

  24. Fallara G, Capogrosso P, Schifano N, et al. Ten-year follow-up results after holmium laser enucleation of the prostate. Eur Urol Focus. 2021;7:612–7. Single arm study showing 4.8% reoperation rate at 10 years.

    Article  PubMed  Google Scholar 

  25. Ibrahim A, Alharbi M, Elhilali MM, Aubé M, Carrier S. 18 years of holmium laser enucleation of the prostate: a single center experience. J Urol. 2019;202:795–800. Single arm study showing 4.8% reoperation rate at 10 years.

    Article  PubMed  Google Scholar 

  26. Kaplan SA. Re: efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study). J Urol. 2019;201:415–6.

    Article  PubMed  Google Scholar 

  27. Carnevale FC, Iscaife A, Yoshinaga EM, Moreira AM, Antunes AA, Srougi M. Transurethral resection of the prostate (TURP) versus original and PErFecTED Prostate Artery Embolization (PAE) Due to Benign Prostatic Hyperplasia (BPH): preliminary results of a single center, prospective, urodynamic-controlled analysis. Cardiovasc Intervent Radiol. 2016;39:44–52.

    Article  PubMed  Google Scholar 

  28. Abt D, Müllhaupt G, Hechelhammer L, Markart S, Güsewell S, Schmid H-P, Mordasini L, Engeler DS. Prostatic artery embolisation versus transurethral resection of the prostate for benign prostatic hyperplasia: 2-yr outcomes of a randomised, open-label, single-centre trial. Eur Urol. 2021;80:34–42.

    Article  PubMed  Google Scholar 

  29. Jung JH, McCutcheon KA, Borofsky M, Young S, Golzarian J, Kim MH, Narayan VM, Dahm P. Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev. 2022. https://doi.org/10.1002/14651858.CD012867.pub3. Systematic review and meta-analysis suggesting higher reintervention rate with PAE than TURP - limited evidence to date.

  30. Nguyen D-D, Misraï V, Bach T, Bhojani N, Lingeman JE, Elterman DS, Zorn KC. Operative time comparison of aquablation, greenlight PVP, ThuLEP, GreenLEP, and HoLEP. World J Urol. 2020;38:3227–33.

    Article  PubMed  Google Scholar 

  31. Menon A, Gilling PJ. Aquablation and question of hemostasis. Can J Urol. 2021;28(3):10691.

    PubMed  Google Scholar 

  32. Gross AJ, Lipp MJ, Baumbach R, Becker B, Vogt K, Rosenbaum C, Netsch C. Rectal perforation after aquablation of the prostate: lessons learned the hard way. World J Urol. 2021;39:3441–6.

    Article  CAS  PubMed  Google Scholar 

  33. Yafi FA, Tallman CT, Seard ML, Jordan ML. Aquablation outcomes for the U.S. cohort of men with LUTS due to BPH in large prostates (80–150 cc). Int J Impot Res. 2018;30:209–14.

    Article  PubMed  Google Scholar 

  34. Gilling PJ, Barber N, Bidair M, Anderson P, Sutton M, Aho T, Kramolowsky E, Thomas A, Cowan B, Roehrborn C. Randomized controlled trial of aquablation versus transurethral resection of the prostate in benign prostatic hyperplasia: one-year outcomes. Urology. 2019;125:169–73.

    Article  PubMed  Google Scholar 

  35. Gilling P, Barber N, Bidair M, et al. Two-year outcomes after aquablation compared to TURP: efficacy and ejaculatory improvements sustained. Adv Ther. 2019;36:1326–36.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Tokarski AT, Leong JY, Roehrborn CG, Shvero A, Das AK. Aquablation of the prostate: a review and update. Can J Urol. 2021;28(S2):17–21.

    PubMed  Google Scholar 

  37. Gilling PJ, Barber N, Bidair M, et al. Five-year outcomes for aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH. Can J Urol. 2022;29:10960–8. Five-year outcomes from the WATER trial, comparing Aquablation to TURP in men with glands 30-80cc in volume.

    PubMed  Google Scholar 

  38. Bhojani N, Bidair M, Kramolowsky E, et al. Aquablation therapy in large prostates (80-150 mL) for lower urinary tract symptoms due to benign prostatic hyperplasia: final WATER II 5-Year clinical trial results. J Urol. 2023;210:143–53. Five-year outcomes from the WATER II trial, a single arm trial evaluating Aquablation for men with glands 80-150cc in volume.

    Article  PubMed  Google Scholar 

  39. Desai M, Bidair M, Bhojani N, Trainer A, Arther A, Kramolowsky E, Doumanian L, Elterman D, Kaufman RP Jr, Lingeman J, Krambeck A, Eure G, Badlani G, Plante M, Uchio E, Gin G, Goldenberg L, Paterson R, So A, et al. Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 2-year results. Can J Urol. 2020 Apr;27(2):10147–53.

    PubMed  Google Scholar 

  40. Zorn KC, Bidair M, Trainer A, et al. Aquablation therapy in large prostates (80–150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3-year trial results. BJUI Compass. 2022;3:130–8.

    Article  PubMed  Google Scholar 

  41. Ewing B, Alavi-Dunn N, Hamann H, Danforth T. Large pelvic hematoma following UroLift procedure causing renal failure requiring dialysis. Urol Case Rep. 2020;34:101514.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Cai PY, Gaffney C, Vanden Berg RW, Shoag JE, Lee RK. Pelvic hematoma following Urolift procedure for BPH. Urology. 2020;137:208.

    Article  PubMed  Google Scholar 

  43. Pollock GR, Bergersen A, Chaus FM, Gretzer M. Pelvic hematoma following UroLift procedure for BPH. Urology. 2019;133:e3–4.

    Article  PubMed  Google Scholar 

  44. Krishnendu B, Rajiv P. Migration of Urolift clip into the bladder causing haematuria 3-years after insertion: a rare delayed complication of prostatic urolift. UNOAJ. 2021;9:68–9.

    Article  Google Scholar 

  45. Rukstalis D, Grier D, Stroup SP, Tutrone R, deSouza E, Freedman S, David R, Kamientsky J, Eure G. Prostatic Urethral Lift (PUL) for obstructive median lobes: 12 month results of the MedLift study. Prostate Cancer Prostatic Dis. 2019;22:411–9.

    Article  PubMed  Google Scholar 

  46. Miller LE, Chughtai B, Dornbier RA, McVary KT. Surgical reintervention rate after prostatic urethral lift: systematic review and meta-analysis involving over 2,000 patients. J Urol. 2020;204:1019–26. Systematic review of Urolift outcomes - accounts for loss to follow up via life-tables type adjustment.

    Article  PubMed  Google Scholar 

  47. Tanneru K, Gautam S, Norez D, Kumar J, Alam MU, Koocheckpour S, Balaji KC, Joseph C. Meta-analysis and systematic review of intermediate-term follow-up of prostatic urethral lift for benign prostatic hyperplasia. Int Urol Nephrol. 2020;52:999–1008.

    Article  PubMed  Google Scholar 

  48. Roehrborn CG, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, Cantwell AL, McVary KT, Te AE, Gholami SS, Moseley WG, Chin PT, Dowling WT, Freedman SJ, Incze PF, Coffield KS, Herron S, Rashid P, Rukstalis DB. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017;24(3):8802–13.

    PubMed  Google Scholar 

  49. Gratzke C, Barber N, Speakman MJ, et al. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. BJU Int. 2017;119:767–75.

    Article  PubMed  Google Scholar 

  50. McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2021;206:715–24. Reports 5 year outcomes from the REZUM II trial comparing Rezum to sham surgery.

    Article  PubMed  Google Scholar 

  51. Tutrone RF, Schiff W. Early patient experience following treatment with the UroLift prostatic urethral lift and Rezum steam injection. Can J Urol. 2020;27:10213–9.

    PubMed  Google Scholar 

  52. Fernández-Guzmán E, Asensio Matas A, Capape Poves V, Rioja Zuazu J, Garrido Abad P, Martínez-Salamanca JI, Quintana Franco LM, Justo-Quintas J, Romero-Otero J, Domínguez-Esteban M. Preliminary results of a national multicenter study on the treatment of LUTS secondary to benign prostatic hyperplasia using the Rezūm® steam system. Actas Urológicas Españolas (English Edition). 2022;46:310–6.

    Article  Google Scholar 

  53. Alegorides C, Fourmarier M, Eghazarian C, Lebdai S, Chevrot A, Droupy S. Treatment of benign prostate hyperplasia using the Rezum® water vapor therapy system: Results at one year. Progrès en Urologie. 2020;30:624–31.

    Article  CAS  PubMed  Google Scholar 

  54. Ines M, Babar M, Singh S, Iqbal N, Ciatto M. Real-world evidence with The Rezūm System: A retrospective study and comparative analysis on the efficacy and safety of 12 month outcomes across a broad range of prostate volumes. The Prostate. 2021;81:956–70.

    Article  CAS  PubMed  Google Scholar 

  55. Bassily D, Wong V, Phillips JL, Fraiman M, Bauer R, Dixon CM, Wong NC (2021) Rezūm for retention—retrospective review of water vaporization therapy in the management of urinary retention in men with benign prostatic hyperplasia. The Prostate 81:1049–1054. Demonstrates 80% six-month success rate in treating catheter-dependent urinary retention in small cohor of patients.

  56. Tomera KM, Hellerstein DK. Transurethral microwave thermotherapy (TUMT). Contemp Urol. 1992;4(72–75):80–2.

    Google Scholar 

  57. Raizenne BL, Zheng X, Mao J, Zorn KC, Cho A, Elterman D, Bhojani N, Sedrakyan A, Chughtai B. Real-world data comparing minimally invasive surgeries for benign prostatic hyperplasia. World J Urol. 2022;40:1185–93. Compares Urolift with TUMT - 3 year failure rates are similar.

    Article  CAS  PubMed  Google Scholar 

  58. Olweny EO, Jow SL, Jow WW. Prolieve transurethral thermodilatation for treatment of symptomatic benign prostatic hyperplasia: 5-year results from a prospective multicenter trial. J Endourol. 2022;36:117–23.

    Article  PubMed  Google Scholar 

  59. Franco JVA, Garegnani L, Escobar Liquitay CM, Borofsky M, Dahm P. Transurethral microwave thermotherapy for benign prostatic hyperplasia: an updated Cochrane review. World J Mens Health. 2022;40:127–38. Suggests that TUMT results in much higher retreatment rates compared to TURP.

    Article  PubMed  Google Scholar 

  60. Miller PD, Kastner C, Ramsey EW, Parsons K. Cooled thermotherapy for the treatment of benign prostatic hyperplasia: Durability of results obtained with the Targis system. Urology. 2003;61:1160–4.

    Article  PubMed  Google Scholar 

Download references

Funding

No funding was received for this article.

Author information

Authors and Affiliations

  1. Department of Urology, Massachusetts General Hospital, Harvard Medical School, GRB - Suite 1100, Boston, MA, 02114, USA

    Jason M. Kowitz & Michelle M. Kim

Authors
  1. Jason M. Kowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michelle M. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

J.K and M.K conceptualized manuscript. J.K wrote the main manuscript text and prepared Table 1 and 2. All authors reviewed the manuscript.

Corresponding author

Correspondence to Michelle M. Kim.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kowitz, J.M., Kim, M.M. Long-Term Failure Rates Among Interventions for Benign Prostatic Obstruction. Curr Bladder Dysfunct Rep (2024). https://doi.org/10.1007/s11884-024-00741-x

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11884-024-00741-x

Keywords

Search

Navigation